Prestige Brands Holdings, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2012, in the company’s fiscal year ending March 31, 2013. The filing identifies the registrant as Prestige Brands Holdings, Inc. (not Prestige Consumer Healthcare Inc.). Amounts below are in U.S. dollars.
Business context and results
The company markets and distributes over-the-counter healthcare and household-cleaning products, primarily in the United States and Canada. Results include the GSK brands acquired in January and March 2012; the acquired operations contributed $51.4 million of revenue in the quarter and $103.0 million in the six-month period.
| Metric | Three months ended Sep. 30, 2012 | Prior year | Six months ended Sep. 30, 2012 | Prior year |
|---|---|---|---|---|
| Total revenue | $161.9 million | $105.5 million | $308.9 million | $200.8 million |
| Operating income | $51.2 million | $29.4 million | $95.0 million | $56.6 million |
| Net income | $19.2 million | $12.9 million | $33.9 million | $27.7 million |
| Diluted EPS | $0.38 | $0.26 | $0.66 | $0.55 |
| Gross margin | 55.9% | 51.1% | 56.4% | 51.7% |
Revenue increased 53.4% for the quarter and 53.8% for the six months, principally from the GSK acquisition. OTC Healthcare revenue rose 74.3% in the quarter and 75.7% for six months; Household Cleaning revenue declined 9.4% and 11.4%, respectively, with Comet weakness a key factor. Gross-margin improvement primarily reflected acquired brands’ lower cost of sales and a larger OTC mix. Operating margins were approximately 31.6% for the quarter and 30.8% for six months.
Cash flow, debt and liquidity
- Six-month operating cash flow was $60.4 million, versus $33.5 million a year earlier. Investing used $5.5 million; financing used $44.9 million. Cash ended at $29.0 million, up from $19.0 million at March 31, 2012.
- At September 30, principal debt was $1.09 billion (carrying value, net of discount, $1.080 billion), down from $1.135 billion at March 31. The company repaid $70 million on its term loan and had net revolver borrowings of $25 million.
- The ABL revolver capacity was increased to $75 million; with $25 million drawn, the company reported $50 million of remaining borrowing capacity. Management reported compliance with debt covenants and expected ongoing compliance.
- Six-month interest expense was $39.5 million, compared with $16.9 million, mainly because acquisition financing increased average debt outstanding. Variable-rate debt was $590 million; management estimated a one-percentage-point rate increase would raise pretax expense and cash outflows by about $3.0 million over six months.
Outlook, risks and unusual items
- No revenue or earnings guidance is provided. Management estimated a 38.9% effective tax rate for the remaining fiscal-year quarters, excluding discrete items.
- Household Cleaning faced declining demand and promotional pressure, reducing segment gross profit and contribution margin. Management also cited potential raw-material, packaging and transportation inflation.
- A third-party manufacturer serving an international brand filed for bankruptcy. Supply had been insufficient, costs had risen, and the company was seeking alternative suppliers; the current supply commitment was through calendar 2012. The filing warns that replacement qualification may take time.
- Risks include dependence on major retailers and outside manufacturers, product liability and recalls, competition and private-label pressure, acquisition integration, and substantial indebtedness. Walmart represented 16.3% of quarterly gross revenue and 20.3% of receivables at period-end.
- General and administrative costs included $1.0 million for office lease termination and, for the six months, $0.5 million related to an unsolicited acquisition proposal. The prior-year six-month comparison included a $5.1 million pretax litigation settlement gain.
- On October 31, 2012, the company sold the Phazyme brand acquired from GSK and used proceeds to repay debt; it expected no significant impact. The GSK purchase-price allocation remained preliminary.
- The company disclosed corrections to prior consolidating schedules for intercompany accounting and presentation. It concluded the revisions were not material to consolidated financial statements and stated there were no changes to the consolidated financial statements.
Most important facts for investors to verify
- How much of ongoing revenue and margin growth is organic versus attributable to the GSK brands, and whether acquired-brand performance is sustainable.
- Debt-service capacity, variable-rate exposure, covenant headroom and actual availability under the $75 million ABL revolver.
- Progress in replacing the bankrupt manufacturer and the effect of higher supply costs or product shortages.
- Trends in Comet and other Household Cleaning products, including whether promotional spending can restore demand and margins.
- Final GSK purchase-price allocation and the financial effect of the subsequent Phazyme sale.